Literature DB >> 30801479

ACOG Committee Opinion No. 772: Immunization Implementation Strategies for Obstetrician-Gynecologists.

.   

Abstract

Immunization against vaccine-preventable diseases is an essential component of women's primary and preventive health care. Many studies have shown that a recommendation from an obstetrician-gynecologist or other health care provider for a vaccine is one of the strongest influences on patient acceptance. Obstetrician-gynecologists and other health care providers should develop a standard process for assessing and documenting the vaccination status of patients and for recommending and administering vaccines. If allowed by state law, obstetrician-gynecologists and other health care providers are encouraged to institute standing orders for indicated immunizations. Obstetrician-gynecologists and other health care providers are encouraged to stock and, ideally, administer commonly recommended vaccines in their offices. Studies show that immunization rates are higher when a health care provider can offer and administer the vaccine during the same visit, as opposed to recommending vaccination and referring the patient elsewhere to receive the vaccine. Given the demonstrated efficacy and safety of vaccines and the large potential for prevention of many infectious diseases that affect adolescents, adults, pregnant women, and newborns, obstetrician-gynecologists should include immunizations as an integral part of their practice. This Committee Opinion has been revised to incorporate additional strategies for obstetrician-gynecologists to consider implementing to enhance their immunization programs.

Entities:  

Mesh:

Year:  2019        PMID: 30801479     DOI: 10.1097/AOG.0000000000003130

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  1 in total

1.  Tetanus vaccine during pregnancy: data of a tertiary hospital in Turkey

Authors:  Gülşah Dağdeviren; Gökçen Örgül; Aykan Yücel; Dilek Şahin
Journal:  Turk J Med Sci       Date:  2020-12-17       Impact factor: 0.973

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.